Exelixis Starts Phase 2/3 Trial in Previously Untreated Recurrent or Metastatic Head and Neck Cancer

 STELLAR-305 is Exelixis’ first pivotal study in squamous cell carcinoma of the head and neck –

– Trial will evaluate the potential of inhibition of VEGF, MET and AXL, which are elevated in these tumors –

https://www.biospace.com/article/releases/exelixis-announces-initiation-of-the-stellar-305-phase-2-3-pivotal-trial-evaluating-zanzalintinib-in-combination-with-pembrolizumab-in-patients-with-previously-untreated-recurrent-or-metastatic-head-and-neck-cancer/